Halozyme Therapeutics (HALO) Receivables (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Receivables data on file, last reported at $458.0 million in Q1 2026.

• On a quarterly basis, Receivables rose 50.35% year-over-year to $458.0 million in Q1 2026; TTM through Mar 2026 was $458.0 million, a 50.35% increase from a year earlier, with the FY2025 full-year figure at $441.3 million, up 34.23% from the prior year.
• Receivables for Q1 2026 stood at $458.0 million, up from $441.3 million in the prior quarter.
• Over the last five years, Receivables for HALO reached as high as $458.0 million in Q1 2026 and fell as low as $113.8 million in Q1 2022.
• Historically, Receivables has averaged $274.4 million across 5 years, with a median of $270.7 million in 2023.
• Across the five-year window, Receivables surged 168.54% in 2022 and retreated 27.48% in 2023, its largest moves.
• Year by year, Receivables stood at $187.0 million in 2022, then gained by 25.8% to $235.2 million in 2023, then jumped by 39.77% to $328.8 million in 2024, then soared by 34.23% to $441.3 million in 2025, then climbed by 3.79% to $458.0 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $458.0 million in Q1 2026, $441.3 million in Q4 2025, and $346.0 million in Q3 2025.